Double CAR t attack: new hope for kids with tough leukemia
NCT ID NCT06408194
First seen Feb 11, 2026 · Last updated Jun 15, 2026 · Updated 14 times
Summary
This study tests whether giving a second type of CAR T-cell therapy (targeting CD22) after the standard CD19 CAR T treatment is safe and can help children and young adults whose B-cell leukemia has returned or not responded to other treatments. About 20 participants will receive the CD22 CAR T cells 28 to 42 days after their CD19 CAR T infusion. The goal is to find the best dose and see if this approach can reduce or eliminate leukemia with manageable side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.